Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
36 participants
INTERVENTIONAL
2021-10-27
2022-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness Pulmonary Telerehabilitation and Cognitive Telerehabilitation in COPD Patients
NCT05222295
Tele-coaching in Patients With COVID-19
NCT04791072
Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection
NCT04365738
Tele-rehabilitation Versus Home Exercise Program in COVID-19
NCT04482634
The Effect of Telerehabilitation-Based Respiratory Exercise Programs on Lung Capacity
NCT06303479
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
informed program
will informed after COVID 19
home exercise program group
this group will implement COVID 19 home exercise program.
home exercise program
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
telerehabilitation group
this group will implement COVID 19 telerehabilitation program.
telerehabilitation
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
telerehabilitation
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
home exercise program
While telerehabilitation sessions will be applied to the participants in the telerehabilitation group for 6 weeks, home exercise program will be given to the home exercise program group and will be applied for 6 weeks.
informed program
will informed after COVID 19
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Do not have any orthopedic or neurological disease that will affect exercise capacity,
* Individuals who can take and execute verbal orders,
* Have had COVID-19 and at least 2 weeks have passed since the completion of the treatment,
* Individuals who have a computer or smart phone with a camera and internet connection and have the ability to use it (the participant himself or one of his family members living in the same house),
* Individuals who are sedentary (those whose physical activity level is inactive according to the Turkish version of the International Physical Activity Questionnaire (UFAA)),
* Having dyspnea at level 2 or 3 on the Medical Research Council Dyspnea Scale.
Exclusion Criteria
* Individuals who cannot be contacted,
* Individuals with chronic heart disease,
* Those with concomitant uncontrolled disease; uncontrolled hypertension (resting blood pressure ≥160 /100mmHg), uncontrolled diabetes (random instantaneous blood glucose\>16.7 mmol/l, HbA1C\>7.0%),
* Those with concomitant severe organic disease (unstable hemodynamic heart disease, heart failure causing movement limitation, unstable angina, MI or other cardiac disease in the last 12 years),
* Individuals with cerebrovascular disease in the last 6 months,
* Those with digestive system ulcer, thyroid dysfunction or active stage of tuberculosis,
* Patients with Chronic Kidney Failure stage 3 and above according to Glomerular Filtration Rate (GFR),
* Individuals who have undergone intraraticular medication or surgery from their lower extremities in the last 6 months,
* Individuals who cannot walk independently,
* Individuals with any mental illness that may prevent them from living independently or receiving treatment,
* Uncooperative individuals for assessment and rehabilitation programs,
* Those with alcohol or substance addiction,
* Those who are pregnant, suspected of pregnancy or considering becoming pregnant,
* Participants in another study within the last 3 months or currently.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bandırma Onyedi Eylül University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Canan Demir
Research Assistant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bandırma Onyedi Eylül University, Faculty of Health Sciences, Physiotherapy and Rehabilitation Department
Balıkesir, Bandırma, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDemir
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.